Depression – Pipeline Review, H2 2018 –

September 14, 2018 /ResearchByMarkets/— “Depression – Pipeline Review, H2 2018“, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics. 

Report Highlights

Depression – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 16, 33, 30, 76, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.



– The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
– The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 


Companies Mentioned: 
Acadia Pharmaceuticals Inc
Ache Laboratorios Farmaceuticos SA
Adamed Sp z oo
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Albany Molecular Research Inc
Alkermes Plc
Allergan Plc
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
BioCrea GmbH
Bionomics Ltd
BioXcel Therapeutics Inc
Blackthorn Therapeutics Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Calico LLC
Celgene Corp
Cellix Bio Pvt Ltd
Celon Pharma SA
Cerecor Inc
Clera Inc
Delpor Inc
Eisai Co Ltd
Eli Lilly and Co
Fabre-Kramer Pharmaceuticals Inc
FPRT Bio Inc
GlaxoSmithKline Plc
GliaCure Inc
H. Lundbeck AS
Heptares Therapeutics Ltd
Impel NeuroPharma Inc
Intas Pharmaceuticals Ltd
IntelGenx Corp
Intra-Cellular Therapies Inc
Jiangsu Nhwa Pharmaceutical Corp Ltd
Johnson & Johnson
Karuna Pharmaceuticals Inc
KemPharm Inc
Kissei Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Mapi Pharma Ltd
Mapreg SAS
MedinCell SA
Medlab Clinical Ltd
Meta-IQ ApS
Mitsubishi Tanabe Pharma Corp
Navitor Pharmaceuticals Inc
Neuralstem Inc
Neurocrine Biosciences Inc
NeuroNascent Inc
Nippon Chemiphar Co Ltd
Novartis AG
Omeros Corp
Otsuka Holdings Co Ltd
Pfizer Inc
Pherin Pharmaceuticals Inc
Protagenic Therapeutics Inc
Relmada Therapeutics Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
Shenox Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
Sound Pharmaceuticals Inc
Sumitomo Chemical Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Syntropharma Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Trevena Inc
VistaGen Therapeutics Inc
Zysis Ltd

Get in touch with us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.